Literature DB >> 9918582

Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.

M H Perrin1, S W Sutton, L A Cervini, J E Rivier, W W Vale.   

Abstract

The characteristics of a high-affinity antagonist radioligand are compared with those a high-affinity agonist in binding to the cloned corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2) and to the native receptors that exist in rat cerebellum and brain stem. The relative potencies of CRF antagonists and agonists to the two types of cloned CRF receptors overexpressed stably in Chinese hamster ovary cells are determined using the antagonist radioligand 125I- [DTyr1]astressin (Ast*), and the agonist radioligand, 125I -[Tyr0]rat urocortin (Ucn*). The inhibitory binding constants (Ki) of astressin and urocortin are 1 to 2 nM for all receptors and are independent of which radioligand is employed. Astressin binds with high affinity to the native cerebellar/brain stem receptor and relative potencies of selected CRF analogs determined with Ast* on the native receptor are similar to those obtained for the cloned CRF-R1. The specific binding of Ast* to endogenous brain receptors is greater than that of Ucn*, resulting in more sites being detected by the antagonist than by the agonist. In contrast to another CRF agonist, the binding of Ucn* to the cloned receptors is relatively insensitive to guanyl nucleotides at both 20 degreesC and 37 degreesC; however, its binding to the native receptor is displaced by guanyl nucleotides at 37 degreesC and, to a lesser degree, at 20 degreesC. As expected, the binding of the antagonist Ast* is not affected by guanyl nucleotides. Because it is a high-affinity, specific CRF antagonist, astressin is eminently suitable as a ligand for detection and characterization of both endogenous and cloned CRF receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918582

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

1.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor.

Authors:  Christy R R Grace; Marilyn H Perrin; Michael R DiGruccio; Charleen L Miller; Jean E Rivier; Wylie W Vale; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 2.  Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.

Authors:  Yvette Taché; Bruno Bonaz
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand.

Authors:  Christy Rani R Grace; Marilyn H Perrin; Jozsef Gulyas; Michael R Digruccio; Jeffrey P Cantle; Jean E Rivier; Wylie W Vale; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-12       Impact factor: 11.205

4.  Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.

Authors:  Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever
Journal:  Bioconjug Chem       Date:  2008-09-23       Impact factor: 4.774

5.  Effect of omega-3 fatty acids on haemostatic functions in urocortin-treated obese rats.

Authors:  Ahmed A El-Gendy; Amr M Abbas
Journal:  J Physiol Biochem       Date:  2014-07-26       Impact factor: 4.158

6.  Polymer-based cell-free expression of ligand-binding family B G-protein coupled receptors without detergents.

Authors:  Christian Klammt; Marilyn H Perrin; Innokentiy Maslennikov; Ludovic Renault; Martin Krupa; Witek Kwiatkowski; Henning Stahlberg; Wylie Vale; Senyon Choe
Journal:  Protein Sci       Date:  2011-05-03       Impact factor: 6.725

Review 7.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

8.  Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome.

Authors:  Y Sagami; Y Shimada; J Tayama; T Nomura; M Satake; Y Endo; T Shoji; K Karahashi; M Hongo; S Fukudo
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

9.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

Authors:  Eyup Akgün; Meike Körner; Fan Gao; Kaleeckal G Harikumar; Beatrice Waser; Jean Claude Reubi; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

10.  Corticotropin-releasing factor within the central nucleus of the amygdala and the nucleus accumbens shell mediates the negative affective state of nicotine withdrawal in rats.

Authors:  Catherine A Marcinkiewcz; Melissa M Prado; Shani K Isaac; Alex Marshall; Daria Rylkova; Adrie W Bruijnzeel
Journal:  Neuropsychopharmacology       Date:  2009-01-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.